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Abstract Thyroid peroxidase (TPO) is the key enzyme in
thyroid hormone production and a universal autoantigen in
Graves’ and other autoimmune thyroid diseases. We wished
to explore the expression of TPO and whether it was
affected by thionamide antithyroid drugs. We studied
recombinant TPO, stably expressed by a Chinese hamster
ovary cell line (CHO-TPO) and transiently expressed TPO-
enhanced green fluorescent protein (eGFP) and -FLAG
fusion proteins. Immunoblotting of CHO-TPO cell extracts
showed high-molecular weight (HMW) TPO isoforms that
were resistant to reduction, as well as 110 kDa monomeric
TPO. Co-immunoprecipitation and enzyme-linked-
immunosorbent assay (ELISA) binding studies of FLAG-
and eGFP-tagged TPO demonstrated TPO dimerisation.
CHO-TPO cells cultured in methimazole (MMI) for 10 days
showed a significant reduction in HMW-TPO isoforms at
MMI concentrations of 1µM and above (p<0.01), whereas
monomeric TPO expression was unchanged. We observed a
similar reduction in HMW-TPO in CHO-TPO cells cultured
in propylthiouracil (10µM and above). Binding of Graves’
disease patient sera and TPO-Fabs to enzymatically active
TPO that was captured onto solid phase was not abrogated
by MMI. The cellular localisation of TPO in CHO-TPO
cells was unchanged by MMI treatment. Our demonstration
of homodimeric TPO and the reduction in HMW-TPO
isoforms during thionamide treatment of CHO-TPO cells
shows, for the first time, an effect of thionamides on TPO
structure. This suggests a structural correlate to the effect of
thionamides on TPO enzymatic activity and opens up a
novel potential mechanism for thionamide immunomodu-
lation of autoimmune thyroid disease.
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Introduction
Thyroid peroxidase (TPO) is the commonest autoantigen
for mankind, 5% to 18% of individuals in Westernised
populations showing circulating anti-TPO antibodies, with
an age-related increase in prevalence. Furthermore, anti-
TPO antibodies are practically universal in individuals with
all clinical forms of autoimmune thyroid disease (AITD)
[1]. TPO functions as a cell-surface enzyme and is
predicted to have four modular domains [2]: an amino-
terminal myeloperoxidase (MPO)-like domain, a
complement-control protein (CCP)-like domain (also
known as a sushi domain), an epidermal growth factor-like
domain, and a short carboxy-terminal membrane-anchoring
domain. The anti-TPO immune response in AITDs is
dominated by antibodies that recognise specific conforma-
tional epitopes, termed immunodominant regions, which
appear to be composed of structural residues from both its
MPO-like and CCP-like domains [3–6]. The enzymatic
activity of TPO is essential for thyroid hormone biosynthe-
sis, and molecular abnormalities causing defective TPO
activity lead to profound congenital hypothyroidism and
goitre [7].
Thionamide compounds, including propylthiouracil
(PTU), methimazole (MMI), and carbimazole, have been
used to treat Graves’ disease and other forms of hyperthy-
roidism for more than 60 years [8]. Their antithyroid action
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for TPO. The first step in thyroid hormone synthesis is
iodination of thyroglobulin tyrosyl residues. In the presence
of thionamide, TPO iodinates the sulphenyl group of the
thionamide drug, instead of the thyroglobulin tyrosyl
residue. During treatment of hyperthyroidism, thionamides
accumulate in the thyroid follicular cells over time. Their
increasing concentration results in reduced thyroid hormone
synthesis and eventually leads to a complete blockade of
thyroid hormone production [9]. An additional effect of
thionamides is that they may result in a lasting remission
from hyperthyroid Graves’ disease, during which, certain
individuals may become almost indefinitely euthyroid, even
after thionamide administration is stopped [10, 11]. This
durable remission of Graves’ disease occurs in 40% to 50%
of patients who are treated with thionamides and appears
to occur irrespective of which compound has been
administered, or the dose used [12]. Optimal remission
rates of hyperthyroid Graves’ disease occur after 6 to
18 months of thionamide administration and are associated
with a reduction in circulating antithyroid antibodies,
including those directed against the thyrotropin receptor
(TSHR) and TPO epitopes [13, 14]. This latter, ‘remis-
sion-inducing’ property of thionamides in Graves’ hyper-
thyroidism has been referred to as an immunomodulatory
action. While the enzymatic mechanism for the antithyroid
action of thionamides is well documented, literature
concerning the effects of thionamides on TPO expression
or structure is sparse. Similarly, the molecular basis for the
widely exploited immunomodulatory action of thiona-
mides in Graves’ disease remains unknown, although
many hypotheses have been explored [11, 15, 16]. Bearing
in mind that TPO is a universal autoantigen in AITD and
that the immune responses are directed against conforma-
tional TPO epitopes, we set out to explore the hypothesis
that thionamides may influence the structure of TPO (i.e.,
the conformation of these epitopes) or its subcellular
localisation.
Materials and methods
Cell culture, lysis, and protein extraction
A Chinese hamster ovary cell line that had been stably
transfected with full-length human TPO (CHO-TPO) was
used to generate enzymatically active TPO (a gift from Dr.
Monika Gora (Warsaw) and Prof. Paul Banga (London)).
CHO-TPO cell monolayers were cultured for 7–10 days in
complete media (Hams F12+500µg/ml hygromycin B,
10% foetal bovine serum). Cells were washed three times
in cold phosphate-buffered saline (PBS) before scraping
and pelleting. Cell pellets were resuspended in ice cold
lysis buffer (50 mM Tris–HCl, pH7.3; 150 mM NaCl;
5 mM ethylenediaminetetraacetic acid; 10% glycerol (w/v);
1% Triton X-100 (w/v), protease inhibitors). After two
freeze-thaw cycles, debris was pelleted at 13,000 g for
30 min at 4°C. Supernatants were collected as a source of
TPO and stored at −20°C. Aliquots of each preparation
were tested for peroxidase activity by oxidation of 0.5%
guaiacol in PBS [17].
Immunoblotting
Recombinant human TPO (rhTPO) was prepared as above
with the following exceptions: CHO-TPO cells were
cultured either for 10 days in the presence of MMI (1, 10,
100, and 500 μM) in complete media or for 7 days in
complete media followed by 50 h with 6-PTU (Sigma) (10,
100, and 500 μM) in serum-free media (OptiMEM). Total
protein was standardised by micro-bicinchoninic acid assay
(BCA) assay (Pierce labs) and electrophoresed at 20 mA/
gel on sodium dodecyl sulphate (SDS)-polyacrylamide gels
after mild denaturation by concomitant incubation with
40 mM iodoacetamide and 50 mM dithiothreitol (DTT) in
SDS-loading buffer (0.1 M TrisCl, pH6.8; 20% glycerol,
4% SDS, 0.001% bromophenol blue) for 10 min at 97°C.
Alternative denaturation/reduction buffers including DTT
only, 2-mercaptoethanol, and iodoacetamide alone were
used, as detailed in Fig. 1. Gels were blotted by electro-
transfer onto nitrocellulose (Hybond ECL, GE Healthcare)
for 90 min at 90 V, on ice. After transfer, non-specific
Fig. 1 Recombinant human TPO forms high molecular weight
complexes. Cell extracts, native (A) or denatured (B; 98°C for
10 min) with either 2% 2-ME, 50 mM DTT, 40 mM iodoacetamide
(IAA), or 50 mM DTT and 40 mM IAA, from CHO cells stably-
expressing rhTPO were assessed by immunoblotting with mAb47.
Bands migrating at ~105-110 kDa were observed in all conditions
corresponding to monomeric TPO. High molecular weight TPO
isoforms were also detected above 200 kDa
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milk in Tris-buffered saline and 0.1% Tween 20 (TBST)
overnight, followed by 16 h incubation with a monoclonal
anti-TPO antibody (mAb47, Alexis Biochemicals, UK) in
1% bovine serum albumin (BSA) in phosphate-buffered
saline and 0.1% Tween 20 (PBST). Membranes were
washed in TBST and incubated for 1 h with anti-mouse
IgG alkaline phosphatase conjugate antibody, raised in goat
(1/1,000 in 1% BSA in TBST, Pierce) to detect antibody
binding. Four 5-min washes followed before adding
chemiluminescent substrate (West Dura, Pierce) and expos-
ing to film. Band densitometry was performed using
ImageQuant software and normalised for glyceraldehyde
3-phosphate dehydrogenase (GAPDH) expression in each
lane.
Cloning eGFP/FLAG-TPO
Oligonucleotide primers were designed to flank and overlap
the 3′ and 5′ ends of TPO cDNA, previously cloned into
pcDNA3.1 (gift of Dr. B Rapoport, LA [18]), and
introduced a G to C base change into the stop codon to
allow read-through to C-terminally tagged fusion protein,
as well as XbaI and EcoRI sites for subsequent in-frame
cloning into pCMV14-3xFLAG vector (Sigma) or AgeI and
EcoRI for pEGFP-N1 (Clontech). The full-length cDNA
was polymerase chain reaction (PCR)-amplified using high-
fidelity Phusion polymerase (NEB, Beverly, MA, USA).
The resulting 3 kb bands were sub-cloned into either the
TOPO-pCR-XL (Invitrogen) or pGEM T-easy vectors
(Promega) and ligated into their final vectors. Single clones
positive for full-length TPO were identified by restriction
digest and in-frame integration of the cDNA confirmed by
DNA sequencing. FLAG-tagged bacterial alkaline phos-
phatase (FLAG-BAP) and unconjugated enhanced green
fluorescent protein (eGFP; pEGFP-N1) constructs were
obtained from manufacturers. The unconjugated eGFP
construct will be referred to as eGFP-nil.
Co-immunoprecipitation
CHO cells at 70% confluence were co-transfected with
FLAG-TPO, eGFP-TPO (10µg per 10 cm
2 plate), or their
respective controls: FLAG-BAP, eGFP-nil using Fugene
HD (Roche, UK). After 18 h, proteins were extracted as
previously described. Input samples were retained, and the
remainder pre-cleared for non-specific binding with
protein-G sepharose beads for 1 h. Samples were then
centrifuged at 1,000 g at 4°C for 1 min, the N-terminally
tagged TPO fusion proteins were immunoprecipitated
overnight using their corresponding antibodies: Anti-
FLAG M2 (Sigma), 0.5 μg, or GFP(FL) and GFP(B2;
Santa Cruz Antibodies, CA, USA). Immunoprecipitating
beads were thoroughly washed with lysis buffer and
subjected to SDS-polyacrylamide gel electrophoresis
(PAGE; as above) alongside their corresponding pre-
immunoprecipitated input samples. Immunoblotting was
performed as before with the following exceptions: the
presence of eGFP-TPO was detected with anti-GFP murine
monoclonal or FLAG-TPO using anti-FLAG M2.
Tagged-TPO ELISA
Extracts from CHO cells co-transfected with FLAG-TPO,
and either eGFP-TPO or eGFP-nil were prepared as above.
Samples with equal total protein, assessed by micro-BCA,
were incubated overnight in enzyme-linked-immunosorbent
assay (ELISA) plates pre-coated with anti-FLAG M2 mouse
antibody (100 ng/well) and blocked with 2% BSA in PBST.
After thorough washing with PBST, GFP(FL) rabbit antibody
was added for 1 h and detected with anti-rabbit AP-conjugate.
Development of para-nitrophenylphosphate (pNPP) was
measured (A405)a f t e r1h .
Bacterial expression of Fab fragments
Four cloned Fabs, TR1.9 and TR1.8; and WR1.7 and
SP1.4, which recognised the human TPO B and A
immunodominant epitopes, respectively, were obtained
(kind gift of Drs. B Rapoport and S McLachlan, LA)
[19]. Starter cultures of XL1-blue Escherichia coli contain-
ing each of the Fab expression constructs were used to
inoculate Superbroth: 30 g/l tryptone, 20 g/l yeast extract,
10 g/l 3-(N-morpholino)propanesulfonic acid, 20 mM
MgCl2, 1% glucose grown at 37°C with shaking. At A595
approximately 0.4 Fab production was induced with 1 mM
isopropyl β-D-1-thiogalactopyranoside for 16 h at 28°C.
Cells were pelleted and after four freeze-thaw cycles were
centrifuged at 30,000 g for 30 min at 4°C. The supernatant
was retained as a source of Fab.
ELISA for TPO antibody binding
mAb47 was used to capture recombinant TPO from CHO-
TPO cell extracts. Binding of Fabs and patient sera to
captured TPO was studied in different MMI (Sigma
Chemicals, Poole, UK) conditions, with MMI added after
Fab or serum binding. Sera that were positive for TPO
antibodies on a conventional chemiluminescent assay
(ADVIA Centaur, Bayer) from 36 patients with AITD were
studied including 30 (29 females) with Graves’ disease, and
six (five females) with autoimmune hypothyroidism (mean
age 47 years, range 18–78). All sera were collected with the
approval of the Northumberland Tyne and Wear local
research ethics committee (Reference number 666).
Ninety-six well ELISA plates (Nunc, maxisorp) were
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well, overnight. After 3× 5 min PBS 0.1% Tween (PBST)
washes, wells were blocked with 2% BSA in PBST for 1 h
and incubated overnight with CHO-TPO cell extracts in
2 mg/ml BSA in PBS. Wells were again washed and
incubated overnight with either Fabs (diluted 1/1,000) or
Graves’ patient sera, individually diluted to 1/500 in 2 mg/ml
BSA in PBST. To study the effect of MMI, wells were
incubated with MMI (500 nM-500 mM) for 30 min at 37°C.
Fab or serum Ig binding was detected with antihuman IgG,
Fab-specific Alk-Phos Conjugate raised in goat (Sigma).
Absorbance (A405) was measured after 1 h incubation pNPP
ELISA substrate (Sigma), using a 96-well-plate spectropho-
tometer (Ascent Multiskan).
Immunocytochemistry
All microscopy was performed using an Axioplan 2 wide-
field microscope with Zeiss Axiovision software. Cells were
seeded after trypsin-passage onto (1.8 cm
2) chamberslides
(Nunc) and grown to near confluence (approximately 2–
3 days). Media was changed to include MMI in complete
Fig. 2 Differentially tagged recombinant human thyroid peroxidase
(rhTPO) forms dimeric complexes in Chinese hamster ovary (CHO)
cells. CHO cells were co-transfected with FLAG- and enhanced green
fluorescent protein (eGFP)-TPO, or their respective control constructs
FLAG-BAP or eGFP-nil. Cell extracts were immunoprecipitated via
their fusion-tags using either anti-FLAG M2, anti-GFP B2, or anti-
GFP FL antibody bound to protein-G sepharose. a FLAG-BAP (a.)
and FLAG-TPO (b.) were immunoprecipitated using the anti-FLAG
sepharose. Anti-GFP detected co-immunoprecipitating bands in the
FLAG-TPO transfected cell extract but not following FLAG-BAP
transfection (c.). b Both GFP antibodies co-immunoprecipitated
FLAG-TPO along with eGFP-TPO (d. and f.) but not in cell extracts
transfected with the eGFP-nil control construct (e. and g.)
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medium was then removed and cells immediately fixed with
fresh 4% paraformaldehyde (PFA) on ice for 15 min. Wells
were washed three times with PBS+100 mM glycine to
remove residual PFA. After culture and fixation, appropriate
wells were permeablised for 15 min with PBST (1% Tween-
20). All wells were then blocked with 3% BSA in PBS for
1 h before incubation with primary antibody in 1% BSA
(1/50 mAb47) for a further hour. Wells were washed three
times with PBS and incubated with anti-mouse IgG
fluorescein isothiocyanate-conjugate (Sigma) for 1 h. Wells
were further washed three times, chambers removed, and
vector shield with 4′,6-diamidino-2-phenylindole (Vector
Laboratories, UK) applied beneath a glass-coverslip.
Statistical analysis
Groups of measurements were compared using two-tailed
t tests, paired by the day of experiment.
Results
High-molecular weight TPO isoforms exist in CHO-TPO
cells
Immunoblotting of extracts from the stably transfected
CHO-TPO cell line with the monoclonal anti-TPO antibody
mAb47 revealed a discrete 110 kDa band and additional
high-molecular weight (HMW) bands in the 220–240 kDa
range. These HMW complexes were resistant to denatur-
ation with conventional reducing agents (Fig. 1). The
110 kDa isoform is consistent with the expected size of
monomeric TPO. As MPO is known to function as a
homodimer, we suspected that the HMW-TPO isoforms
could also be homodimers.
High-molecular weight TPO is a homodimer
FLAG- and eGFP-tagged TPO were transiently co-expressed
in CHO cells, and cell extracts were immunoprecipitated
using antibody-conjugated protein-G sepharose beads. Co-
transfections using FLAG-BAP and eGFP-nil, along with the
tagged TPO constructs were used as controls. Cell extracts
from cells co-transfected with FLAG- and eGFP-TPO
revealed an eGFP reactive band following immunoprecipi-
tation with anti-FLAG coated beads (Fig. 2). Similarly,
immunoprecipitation of the same extracts with anti-GFP
coated beads showed an immunoreactive band to anti-FLAG
antibody. Co-transfected cells with either FLAG-BAP or
eGFP-nil showed no non-specific binding (Fig. 2).
We also looked to confirm TPO dimerisation in an
ELISA system, using cell extracts from FLAG-TPO and
eGFP-TPO co-transfected CHO cells. Plates were coated
with anti-FLAG antibody, to capture FLAG-tagged TPO
and probed with anti-GFP to detect TPO dimer. Extracts
from FLAG-TPO and eGFP-nil co-transfected cells were
used as a control. There was a clear detection of the
GFP-tagged TPO when extracts of the FLAG-TPO and
eGFP-tagged TPO co-transfected cells were studied
(Fig. 3). Whereas, extracts from FLAG-TPO but eGFP-
nil co-transfected cells showed low signal when probed
with anti-GFP Ab. These results confirm that TPO
homodimerises in this system and provides the likely
explanation for the HMW-TPO isoforms seen on immu-
noblotting (Fig. 1).
Thionamide reduces high-molecular weight TPO
expression in CHO-TPO cells
CHO-TPO cells were cultured in MMI or PTU, and cell
extracts were subject to PAGE and immunoblotting. As
before, the anti-TPO antibody mAb47 revealed bands of
110 and 220–240 kDa from untreated CHO-TPO cells
(Fig. 4). Cells grown in MMI for 10 days showed a
reproducible and significant reduction in the HMW-TPO
isoform(s). At an MMI concentration of 1µM, there was a
58% reduction in HMW-TPO bands compared to untreated
cells (p=0.01), as normalised for GAPDH expression.
Greater reductions in these HMW isoforms were found at
higher MMI concentrations (58–82% reduction, all p<0.05;
Fig. 4). In contrast, there was no change in expression of
the 110 kDa TPO isoform during MMI treatment. The
Fig. 3 Demonstration of dimeric thyroid peroxidase (TPO) by tagged
TPO enzyme-linked-immunosorbent assay. FLAG-TPO from Chinese
hamster ovary cells co-transfected with FLAG-TPO and enhanced
green fluorescent protein (eGFP)-TPO, or eGFP-nil constructs was
captured onto solid phase by murine anti-FLAG M2. A rabbit anti-
GFP (FL) antibody detected eGFP-TPO with an increase in the A405
of >900% (mean of three replicates). This optical density was
significantly greater than that observed in the absence of GFP
antibody (p<0.01) or than that of the GFP-nil control (p<0.01)
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24 h of culture in MMI 100µM and persisted for at least
10 days of continuous MMI exposure (data not shown).
As PTU is avidly protein bound, we cultured CHO-TPO
cells in serum-free media with or without PTU to ensure
maximal penetration into the cells. During 50 h exposure of
CHO-TPO cells to PTU in serum-free conditions, we
observed a similar, substantial reduction in HMW-TPO
isoforms of between 34% and 74% across a PTU
concentration gradient from 10 to 500µM (p<0.01 at 100
and 500µM; Fig. 4).
Effect of methimazole (MMI) on recombinant thyroid
peroxidase epitope in vitro
We wished to see whether thionamide effects on TPO
structure could alter its interaction with anti-TPO antibodies.
An ELISA system was developed to examine antibody
binding to TPO by capturing rhTPO from CHO-TPO cell
extracts with mAb47. Binding of sera from 36 TPO antibody
positive AITD patients and from six TPO antibody negative
healthy controls was examined in MMI concentrations from
500 nM to 500 mM. There was no effect of increasing MMI
concentration up to 50 mM on binding of patient or control
sera to captured rhTPO (Fig. 5). At the highest MMI
concentration (500 mM), there appeared to be a direct,
possibly ionic, effect of the MMI on retention of antibody-
TPO complex on the plate (washing and re-probing with
mAb47 revealed no signal). Four Fabs, TR1.9, TR1.8,
WR1.7, SP1.4, two each specific for the TPO immunodo-
minant A or B regions, were tested in the ELISA system.
Similar to the results with patient sera, we observed no
substantial change in Fab binding to anchored TPO after
treatment with MMI (500 nM to 50 mM; Fig. 5).
Fig. 4 High-molecular weight (HMW)-thyroid peroxidase (TPO)
isoforms are reduced in Chinese hamster ovary (CHO)-TPO cultured
with thionamide. Immunoblotting with mAb47 compared levels of
recombinant human TPO (rhTPO) isoforms from CHO-TPO cells
cultured in the presence of (a) methimazole (MMI) for 10 days or (c)
propylthiouracil (PTU) for 50 h immediately prior to harvest. HMW
(>220 kDa) band densities were quantitated from triplicate experi-
ments and normalised as a percentage of that observed in the absence
of thionamide, relative to each sample’s glyceraldehyde 3-phosphate
dehydrogenase for both (b) MMI and (d) PTU. Highly significant
reductions in HMW-TPO occurred at all MMI concentrations
compared to the untreated condition (*p≤0.01, **p<0.05). Likewise,
lower levels of HMW isoforms were observed at all concentrations of
PTU compared to the untreated condition
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Membrane localisation has been proposed as the site of
enzymatically active mature TPO. We wondered whether
thionamide could affect TPO localisation. CHO-TPO cells
were grown in MMI at various pharmacologically relevant
concentrations and studied by immunocytochemistry using
mAb47. TPO expression, frequently in a punctate pattern,
was seen both in a juxta-cell membrane location and in the
cytosol in untreated CHO-TPO cells (Fig. 6). We observed
no change in TPO distribution following exposure to MMI,
either in unpermeabilised or permeabilised cells.
Discussion
We set out to explore the hypothesis that thionamides may
influence the structure of TPO or its subcellular local-
isation. On Western analysis of stably transfected CHO-
TPO cells, we observed 220–240 kDa HMW-TPO bands,
as well as the expected 110 kDa monomeric band (Fig. 1).
Although it is established that MPO, in its mature form,
exists as a homodimer [20, 21] and it was suspected that
TPO would similarly exist in a homodimeric state [22],
our co-immunoprecipitation and ELISA binding studies
with tagged recombinant TPOs (Figs. 2 and 3)c o n f i r m
that TPO does indeed form dimeric complexes, at least in
this system. Furthermore, we made the novel observation
that these dimeric TPO isoforms are dramatically reduced
by thionamide treatment, including both MMI and PTU,
suggesting that these compounds interfere with the normal
structural configuration of TPO. In vivo, thionamides
accumulate in the human thyroid, with MMI reaching
concentrations of 15 μM during therapy for Graves’
disease [23]. The response to MMI that we observed at
in vitro concentrations as low as 1µM mean that this effect
on TPO dimerisation is certainly plausible in vivo at the
pharmacological concentrations that are used in Graves’
disease. Although data on PTU concentrations in human
thyroid is scanty, based on the equivalent potency of PTU
to MMI, the higher concentrations of PTU at which we
observed a similar reduction in HMW-TPO bands are also
consistent with a relevant pharmacological effect in vivo.
Nevertheless, our data on the PTU effect are less robust, as
prolonged culture in serum-free conditions was not
possible, and the intracellular concentration of PTU is
likely to have been substantially influenced by protein
binding.
Fig. 5 Effect of methimazole (MMI) incubation on antibody binding
to thyroid peroxidase (TPO). The effect of MMI on the binding of
autoimmune thyroid disease (AITD) sera or immunodominant region
(IDR)-specific Fabs to recombinant human TPO (rhTPO) was
investigated by sandwich enzyme-linked-immunosorbent serologic
assay incorporating a 30-min MMI incubation (500 nM–500 mM)
following application of the sera or Fab. Substrate absorbance
(measured as A405) was normalised as a percentage of the maximum
observed for each serum or Fab, after non-specific binding to
untransfected Chinese hamster ovary extracts was subtracted. a
Representative absorbance data, from a single experiment, with six
AITD patient sera and a single control. b Normalised data for 36
AITD patient sera and six normal control sera were included. No
significant decrease (two-tailed t test) in binding of Graves’ or control
sera at MMI concentrations up to 50 mM was observed. c Four Fabs,
specific for the TPO IDR were studied in triplicate. Following
incubation with MMI at concentrations of 500 nM–50 mM, there
were no alterations in Fab binding to rhTPO. Substrate absorbance
was dramatically reduced (p≤0.01) at 500 mM MMI in all experi-
ments (we believe a non-specific effect, possibly related to high ionic
content; see “Results”). Data presented as means with bars represent-
ing SEM
R
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homodimeric state and demonstrate that this dimerisation is
sensitive to thionamide treatment. Therefore, we wondered
if these observations could have relevance for thyroid
physiology or the treatment of thyroid diseases. Firstly, it is
possible that part of the inhibitory action of thionamides on
TPO enzymatic activity in vivo is mediated by this drug-
induced change in structure. While this is certainly feasible,
it is already known that the hemi-MPO components of
disassociated MPO dimer retain their activity and that
lactoperoxidase (LPO) exists and functions exclusively in a
monomeric state [20, 24]. A second interesting hypothesis
is that a change in the structure of the TPO conformational
epitope could be responsible for the immunomodulatory
effects of thionamide compounds in Graves’ disease. This
is an attractive hypothesis for several reasons. Firstly, TPO
antibodies are practically universal in AITDs, are known to
recognise distinct and conformational epitopes [3–6], and
are able to mediate direct thyrocyte damage by fixing
complement [25], with a plausible role in perpetuation of
the immune attack in Graves’ disease. Furthermore,
thionamide compounds have established immunomodula-
tory effects in rodent autoimmune thyroiditis. Amelioration
of thyroid infiltration and reduction of thyroid antibody
production have been demonstrated in several models,
including that induced by thyroglobulin in the mouse, by
neonatal thymectomy in the Buffalo rat, and in spontaneous
lymphocytic thyroiditis in the BB/W rat [26–29]. These
observations that thionamide compounds have immuno-
modulatory properties in autoimmune thyroiditides other
than Graves’ disease suggest that their immunomodulatory
effect may be independent of hyperthyroidism and thus
independent of the immune response to the TSHR. Lastly,
because of the well-established interaction of thionamides
with TPO (responsible for the antithyroid action), the
principle of “Occam’s razor” favours that the immunomod-
ulatory action could be an additional consequence of the
same TPO-thionamide interaction. Nevertheless, we cannot
exclude that we are simply observing a non-specific
reducing effect of thionamides on TPO dimeric isoforms
and that similar chronic effects on other multimeric proteins
might be responsible for immunomodulation through a
mechanism unrelated to TPO. However, this does not seem
a likely explanation given the low micromolar concen-
Fig. 6 Effect of methimazole (MMI) on localisation of thyroid
peroxidase (TPO) in stably transfected Chinese hamster ovary
(CHO) cells. CHO-TPO cells were seeded on coverslips and grown
until near confluence, when in the media was changed to include/
exclude MMI (5, 100, and 500 μM). After 24 h, cells were fixed and
left unpermeablised (a) or permeablised (b) with 0.1% Triton X-100
for 30 min. TPO was detected using mab47 and visualised with anti-
mouse IgG fluorescein isothiocyanate (green) conjugate at ×100
magnification. Vectorshield mounting agent contained 4′,6-diamidino-
2-phenylindole to counterstain DNA (blue). Untransfected CHO cells
were included as a control (c). TPO showed juxta-cell membrane and
cytosolic localization, in a punctate pattern. There was no major
change in TPO localisation at any MMI concentration tested
978 J Mol Med (2009) 87:971–980trations of MMI with which we are able to demonstrate an
influence on TPO structure.
Although it is clear that stimulating anti-TSHR anti-
bodies are necessarily present in hyperthyroid Graves’
disease, it is possible that they are neither sufficient nor
the single aetiological cause of the condition. For instance,
neonatal hyperthyroidism caused solely by transplacental
passage of TSHR stimulating antibodies is a self-limiting
disease without perpetuation of hyperthyroidism. In con-
trast to anti-TSHR antibodies, which typically circulate at
nanograms per millilitre quantities in Graves’ disease, anti-
TPO antibodies are found at 1,000-fold higher concentra-
tion [1]. In addition, anti-TPO antibodies have the capacity
to fix complement and to mediate thyrocyte damage
through antibody-dependent cell-mediated cytotoxicity
[25, 30, 31]. Tantalisingly, there is already evidence that
sera from AITD patients may preferentially recognise
HMW-TPO isoforms [32, 33]. Thus, our finding that
thionamides reduce TPO homodimerisation has the poten-
tial to be mechanistically significant. This idea that an
autoimmune disease could be abrogated by a drug-induced
structural change to an autoantigen has existing mechanistic
parallels. It is already well accepted that an immune
response can be generated against neoantigen formed by
the interaction of a drug with a native protein, for example,
in penicillin-induced autoimmune haemolytic anaemia [34].
The proposed mechanism is simply the complementary
situation, in that the thionamide-TPO interaction could, in a
proportion of individuals, disrupt the TPO conformational
epitope to which the autoimmune response has already been
directed. This ‘removal’ of an auto-epitope could lead to a
reduced immune response and a subsequent amelioration of
the disorder. It should also be noted that many autoantigens
are enzymes or cell-surface receptors. These proteins
already exist in at least two structural configurations, and
thus their epitopes may naturally vary in structure depend-
ing upon the state of the receptor (liganded–unliganded) or
enzyme (oxidised–reduced). Alternatively, the relative
flexibility of their molecular structures may make them
particularly susceptible to transformation into a novel
conformational state following interaction with a drug.
Our ELISA experiments, using recombinant human TPO
bound to the solid phase by mAb47 did not appear to show
any effect of MMI on AITD serum or Fab binding to TPO
in vitro. This may simply be that the drug effect requires
dynamically folding nascent TPO proteins to disrupt the
formation of the proper tertiary and quaternary structure.
Thus, these effects may not be present in vitro. Alterna-
tively, dimeric (HMW) TPO may be poorly bound to the
ELISA plate, or the TPO epitope structure may have been
stabilised by its binding to the anchoring mAb47 antibody.
Similarly, we could find no evidence to support the
straightforward possibility that in the presence of thiona-
mide, TPO becomes mislocalised away from the cell
surface. This finding is consistent with a previous study
using MMI applied to native thyrocytes [35].
Our studies advance the field by demonstrating a
molecular effect of thionamides on TPO macromolecular
structure. We demonstrate, for the first time, that HMW-
TPO isoforms, which are likely to be dimeric TPO, are
decreased in the presence of thionamide in vitro. This
observation has possible relevance to a molecular mecha-
nism for both the antithyroid thionamide action and for the
immunomodulation of thyroid autoimmunity by these
drugs. Additional work is needed both in vitro and in vivo
to further illuminate these observations. The possibility of
being able to design a novel antithyroid drug with greater
immunomodulatory properties than the currently available
thionamides, or of being able to predict relapse or remission
of Graves’ disease following drug treatment, based on a
knowledge of antibody repertoire, would have substantial
clinical implications.
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